Overview

Aerosol Inhalation Treatment for Dyspnea

Status:
Completed

Trial end date:
2017-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this protocol is to develop and test optimal delivery of aerosol furosemide, a treatment that has the potential to significantly improve symptom management and enhance the quality of care for patients with intractable dyspnea.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Beth Israel Deaconess Medical Center

Collaborator:

National Institute of Nursing Research (NINR)

Treatments:

Furosemide